[Immunomodulator effect of silymarin therapy in chronic alcoholic liver diseases].
The effects of the hepatoprotective, antioxidant drug silymarin (Legalon) on some cellular immune parameters of patients with histologically proven chronic alcoholic liver disease were studied in a six month double blind study. The lectin induced proliferative activity of the lymphocytes got enhanced, the originally low T cell percentage and the originally high CD8+ cell percentage have been normalized, the antibody-dependent and natural cytotoxicity of the lymphocytes decreased during silymarin therapy. All these changes were significant, while in the placebo group no significant changes occurred, except for a moderate elevation of the T cell percentage. Thus, the immunomodulatory activity of silymarin might be involved in the hepatoprotective action of the drug and improves the depressed immunoreactivity of the patients.
Semmelweis Orvostudományi Egyetem, II. sz. Belklinika, Budapest.
G
G
Deák
G
G
Müzes
I
I
Láng
V
V
Niederland
K
K
Nékám
R
R
Gonzalez-Cabello
P
P
Gergely
J
J
Fehér
D000276:Adjuvants, Immunologic; D000328:Adult; D002986:Clinical Trials as Topic; D005260:Female; D005419:Flavonoids / Q000627:therapeutic use*; D006801:Humans; D008108:Liver Diseases, Alcoholic / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D012838:Silymarin / Q000276:immunology / Q000627:therapeutic use*
D000276:Adjuvants, Immunologic; D005419:Flavonoids; D012838:Silymarin
Silymarin kezelés immunmoduláns hatása krónikus alkoholos májbetegségben.